Press release
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) Investor Alert: Deadline in Lawsuit on July 14, 2025
A Deadline is coming up on July 14, 2025 in the lawsuit for certain investors in Iovance Biotherapeutics, Inc. (NASDAQ: IOVA).
Investors who purchased shares of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) have certain options and there are strict and short deadlines running. Deadline: July 14, 2025. Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
According to the complaint filed in the U.S. District Court for the Northern District of California the plaintiff alleges on behalf of purchasers of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) common shares between August 8, 2024, to May 8, 2025, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between August 8, 2024, to May 8, 2025, the defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Iovance's growth potential; notably, that it was not equipped to generate and drive demand or was otherwise ill equipped to capitalize upon the purported existing demand for its treatments through its network of approved treatment centers.
Those who purchased shares of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) Investor Alert: Deadline in Lawsuit on July 14, 2025 here
News-ID: 4103554 • Views: …
More Releases from Shareholders Foundation, Inc.
Novo Nordisk A/S (NYSE: NVO) Long Term Investor Alert: Investigation of potentia …
An investigation on behalf of current long-term investors in shares of Novo Nordisk A/S (NYSE: NVO) concerning potential breaches of fiduciary duties by certain directors and officers was announced.
Investors who are current long term investors in Novo Nordisk A/S (NYSE: NVO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for long term investors in…
Lawsuit filed for Investors who lost money with shares of Fortinet, Inc. (NASDAQ …
An investor, who purchased shares of Fortinet, Inc. (NASDAQ: FTNT), filed a lawsuit over alleged violations of Federal Securities Laws by Fortinet, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fortinet, Inc. (NASDAQ: FTNT) have certain options and for certain investors are short and strict deadlines running. Deadline: November 21, 2025. NASDAQ: FTNT investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)…
CTO Realty Growth, Inc. (NYSE: CTO) Investor Alert: Deadline in Lawsuit on Octob …
A deadline is coming up on October 07, 2025in the lawsuit filed for certain investors of CTO Realty Growth, Inc. (NYSE: CTO) over alleged securities laws violations by CTO Realty Growth, Inc.
Investors who purchased shares of CTO Realty Growth, Inc. (NYSE: CTO) have certain options and there are strict and short deadlines running. Deadline: October 07, 2025. CTO Realty Growth, Inc. (NYSE: CTO) stockholders should contact the Shareholders Foundation at…
Alert: Lawsuit filed for Investors who lost money with shares of Jasper Therapeu …
An investor, who purchased shares of Jasper Therapeutics, Inc. (NASDAQ: JSPR), filed a lawsuit over alleged violations of Federal Securities Laws by Jasper Therapeutics, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Jasper Therapeutics, Inc. (NASDAQ: JSPR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 18, 2025. NASDAQ: JSPR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for Iovance
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) Long Term Investor Alert: Investiga …
An investigation on behalf of current long-term investors in shares of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) concerning potential breaches of fiduciary duties by certain directors and officers of Iovance Biotherapeutics, Inc. was announced.
Investors who are current long term investors in Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for…
Cellular Immunotherapy Market Projected To Witness Massive Growth, 2025-2032 | I …
The qualitative latest Research report (2025-2032) on the Cellular Immunotherapy Market by Coherent Market Insights Provides a deep dive into key market trends, drivers, challenges, and the competitive landscape. It analyzes market size, revenue, production, and CAGR using validated methodologies to ensure precision. The report highlights tech innovation, pricing trends, consumer behavior, and investment potential - empowering businesses to make informed, strategic moves.
Request a Sample Copy: https://www.coherentmarketresearch.com/samplepages/135590
Focused on growth and…
Lawsuit filed for Investors who lost money with shares of Iovance Biotherapeutic …
An investor, who purchased shares of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), filed a lawsuit i over alleged violations of Federal Securities Laws by Iovance Biotherapeutics, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) have certain options and for certain investors are short and strict deadlines running. Deadline: July 14, 2025. NASDAQ: IOVA investors should contact the Shareholders Foundation at…
Endomucin Market Overall Study Report 2024-2032 | CytoDyn, Iovance Biotherapeuti …
The Endomucin Market research report offers crucial insights into how the industry is evolving, highlighting key drivers of growth and the main revenue streams expected between 2024 and 2032. It's like a compass guiding business through the complexities of the market, presenting not only the current landscape but also the latest innovations shaping its future. This report becomes a strategic ally for companies, stakeholders, and industry players, offering a comprehensive…
Cervical Cancer Therapeutics Market 2023 | Futuristic Trends- Genocea, AstraZene …
This report provides an informative view about the competitive aspect of the global market. It includes detailed picture of the exhibition of a portion of the essential global players working in the Cervical Cancer Therapeutics market. The research study also provides historical record with profits predictions and forecasts from 2023 to 2029. Also, the business manufacturing of the notable manufacturers is also emphasized with technical data in the report.
This report…
Investigation announced for Long-Term Investors in shares of Iovance Biotherapeu …
Certain directors of Iovance Biotherapeutics, Inc are under investigation over potential breaches of fiduciary duties.
Investors who purchased shares of Iovance Biotherapeutics, Inc. (NASDSQ: IOVA) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Iovance Biotherapeutics directors breached their fiduciary duties and caused damage to the company and its shareholders.
San Carlos, CA based Iovance Biotherapeutics,…
